Primerica, Inc. reported robust growth in its investment and savings segment, which now accounts for 42% of its revenue, with a 21% increase in revenue and 31% rise in pre-tax profit in Q2 2026. Although the company faces declining sales in new term life policies and fewer agents, its high reinsurance levels and active share buybacks support ongoing earnings per share growth. Trading at a price-to-earnings ratio of 11.6, below its five-year average, Primerica's valuation appears reasonable given its stable business model and strong capital efficiency. This positions the company well for continued profitability and shareholder returns.
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
